All lobbying filings

LMH STRATEGIC SOLUTIONS

LMH STRATEGIC SOLUTIONS filed a Q3 report for ALKERMES, INC. on October 19, 2026, reporting $60,000 in lobbying income.

Lobbying for ALKERMES, INC. · Biopharmaceutical company

All filings by LMH STRATEGIC SOLUTIONS · Everything ALKERMES, INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Lobbyists on this filing 2

ALANNA TEMME

Previously held: Legislative Director, U.S. Representative Jon Porter
SOPHIE KHANAHMADI

Previously held: Legislative Asst., Rep. Martha Roby; Legislative Asst., Rep. Lee Terry; Staff Asst./LC, Senator Jeff Sessions

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Medicare/Medicaid issues. Medicaid drug rebate program. Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. H.R.946: ORPHAN Cures Act. Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically. Provide guidance and advice regarding mental health, public health and regulatory reform.

Bills named in this filing 1

H.R. 946
ORPHAN Cures Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.